Nobuhiro Kodama

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Yohei Doi, Masaya Hibino, Ryota Hase et al. · Antimicrobial Agents and Chemotherapy · 2020 · 231 citations · Full text

Open-label Trial, Late Favipiravir Therapy, Clinical Infectious Disease +14

The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task Force

Qingbo S. Wang, Ryuya Edahiro, Ho Namkoong et al. · Nature Communications · 2022 · 48 citations · Full text

DRESS Syndrome Caused by Cross-reactivity Between Vancomycin and Subsequent Teicoplanin Administration: A Case Report

Daisuke Miyazu, Nobuhiro Kodama, Daiki Yamashita et al. · American Journal of Case Reports · 2016 · 25 citations · Full text

Comprehensive and long-term surveys of COVID-19 sequelae in Japan, an ambidirectional multicentre cohort study: study protocol

Kensuke Nakagawara, Ho Namkoong, Hideki Terai et al. · BMJ Open Respiratory Research · 2021 · 18 citations · Full text

[The experimental study on causal genesis of moyamoya disease - correlation with immunological reaction and sympathetic nerve influence for vascular changes (author's transl)].

Nahoko Kasai, Shinichi Fujiwara, Nobuhiro Kodama et al. · PubMed · 1982 · 14 citations

Moxibustion, Moyamoya Disease, Causal Genesis +5